Celltrion applies sales approval of Herzuma to enter Japanese market
Celltrion announced it applied sales approval of Herzuma(CT-P6, generic name: trastuzumab), a self-developed anticancer antibody biosimilar, at the Japanese Ministry of Health, Labour and Welfare on the 11th to enter the Japanese market.
Herzuma, an anticancer antibody biosimilar used to treat b...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
